Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 991-998

  Tominaga, Takeshi ^a   Koyama, Hiroki ^b   Toge, Tetsuya ^b   Miura, Shigeto ^b   Sugimachi, Keizo ^b   Yamaguchi, Susumu ^b   Hirata, Koichi ^b   Monden, Yasumasa ^b   Nomura, Yasuo ^b   Toi, Masakazu ^b   Kimijima, Izo ^b   Noguchi, Shinzaburo ^b   Sonoo, Hiroshi ^b   Asaishi, Kazuaki ^b   Ikeda, Tadashi ^b   Morimoto, Tadaoki ^b   Ota, Jun ^b   Ohashi, Yasuo ^b   Abe, Osahiko ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXIFLURIDINE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLOXURIDINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; JAPAN; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RISK; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HUMANS; JAPAN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037445121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.014     Document Type: Article

References (32)

1. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
2. O'Shaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (Cyclophosphamine, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001
3. O'Sharghnessy J, Miles D, Vekelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracyclin-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
4. Niitani H, Kimura K, Saito T, et al: Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer: Multi-institutional cooperative study. Gan To Kagaku Ryoho 12:2044-2051, 1985
5. Taguchi T, Terasawa T, Abe O, et al: A comparative study between 5′-DFUR and tegafur in recurrent breast cancer. Gan To Kagaku Ryoho 12:2052-2060, 1985
6. Kono A, Hara Y, Sugata S, et al: Activation of 5′-deoxy-5- fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31:175-178, 1983
7. Fujita H, Ogawa K, Nakagawa H: Pharmacokinetics of 5′-deoxy-5- fluorouridine (5′-DFUR) by oral administration. Nippon Gan Chiryo Gakkai Shi 18:916-926, 1983
8. Bollag W, Hartmann HR: Tumor inhibitory effects of a new fluorouracil derivative: 5′-Deoxy-5-fluorouridine. Eur J Cancer 16:427-432, 1980
9. Ohta Y, Sueki K, Kitta K, et al: Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann 71:190-196, 1980
10. Ota J, Taguchi T, Sakai K, et al: Combination therapy of doxifluridine (5′-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Gan To Kagaku Ryoho 19:1279-1284, 1992
11. Endo M, Fujimoto-Ouchi K, Matsumoto T, et al: Efficacy of combination chemotherapy of cyclophosphamide and 5′-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1. Gan To Kagaku Ryoho 24:1295-1301, 1997
12. Abe O, Izuo M, Enomoto K, et al: Combination chemotherapy of CPA Adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer. Gan To Kagaku Ryoho 9:866-873, 1982
13. Kakizoe T (ed): Cancer Statistics in Japan Editorial Board: Cancer Statistics in Japan 1999. Tokyo, Japan, Foundation for Promotion of Cancer Research, 1999, p 54
14. Tominaga T, Toi M, Abe O, et al: The effect of adjuvant 5′-deoxy-5-fluorouridine in early stage breast cancer patients: Results from a multicenter randomized controlled trial. Int J Oncol 20:517-525, 2002
15. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, July 1992 (ed 11). Tokyo, Japan, Kanehara Shuppan, 1992, pp 9-10, 63-67
16. Taves DR: Minimization: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 15:443-453, 1974
17. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
18. Schoenfeld DA, Richter JR: Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38:163-170, 1982
19. International Conference on Harmonisation E9 Expert Working Group: ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Statist Med 18:1905-1942, 1999
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
22. Endo M, Shinbori N, Fukase Y, et al: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127-134, 1999
23. Koyama H, Wada T, Nishizawa Y, et al: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977
24. Takashima S, Yasutomi T, Koyama Y, et al: Adjuvant chemotherapy using cyclophosphamide for breast cancer. Gan To Kagaku Ryoho 18:989-994, 1991
25. Brincker H, Rose C, Rank F, et al: Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5:1771-1778, 1987
26. Glick JH, Gelber RD, Goldhisch A, et al: Meeting highlights: Adjuvant therapy for primary breast cancer. J Natl Cancer Inst 84:1479-1485, 1992
27. Watanabe T: State of the art of drug therapy in breast cancer. Gan To Kagaku Ryoho 20:2437-2446, 1993
28. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19:3817-3827, 2001
29. Early Breast Cancer Trialist' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
30. Tamura H, Kojima M, Kobayashi H, et al: Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer. Gan To Kagaku Ryoho 27:993-1002, 2000
31. Watanabe T: Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/ methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients. Cancer Chemother Pharmacol 42:568-70, 1998 (suppl)
32. Hori T, Kodama H, Nishimura S, et al: A randomized study comparing oral and standard regimens for metastatic breast cancer. Oncol Rep 8:1067-1071, 2001